ATE517915T1 - Methode zur identifikation gen-regulierender peptide - Google Patents

Methode zur identifikation gen-regulierender peptide

Info

Publication number
ATE517915T1
ATE517915T1 AT02763111T AT02763111T ATE517915T1 AT E517915 T1 ATE517915 T1 AT E517915T1 AT 02763111 T AT02763111 T AT 02763111T AT 02763111 T AT02763111 T AT 02763111T AT E517915 T1 ATE517915 T1 AT E517915T1
Authority
AT
Austria
Prior art keywords
cell
gene
peptide
analogue
identifying gene
Prior art date
Application number
AT02763111T
Other languages
English (en)
Inventor
Nisar Khan
Robbert Benner
Original Assignee
Biotempt Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt Bv filed Critical Biotempt Bv
Application granted granted Critical
Publication of ATE517915T1 publication Critical patent/ATE517915T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
AT02763111T 2001-10-04 2002-10-04 Methode zur identifikation gen-regulierender peptide ATE517915T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01203748A EP1300418A1 (de) 2001-10-04 2001-10-04 Genregulation durch Oligopeptide
US10/028,075 US20030113733A1 (en) 2001-10-04 2001-12-21 Gene regulator
PCT/NL2002/000639 WO2003029292A2 (en) 2001-10-04 2002-10-04 Gene regulatory peptides

Publications (1)

Publication Number Publication Date
ATE517915T1 true ATE517915T1 (de) 2011-08-15

Family

ID=26077008

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08171373T ATE535542T1 (de) 2001-10-04 2002-10-04 Gen-regulierende peptide
AT02763111T ATE517915T1 (de) 2001-10-04 2002-10-04 Methode zur identifikation gen-regulierender peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08171373T ATE535542T1 (de) 2001-10-04 2002-10-04 Gen-regulierende peptide

Country Status (12)

Country Link
US (5) US20030113733A1 (de)
EP (4) EP1300418A1 (de)
JP (1) JP2005519867A (de)
KR (1) KR20040074975A (de)
CN (2) CN1599753A (de)
AT (2) ATE535542T1 (de)
AU (2) AU2002328028B2 (de)
CA (1) CA2462796A1 (de)
HK (1) HK1063327A1 (de)
IL (2) IL161201A0 (de)
NZ (1) NZ532173A (de)
WO (1) WO2003029292A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
EP1138692A1 (de) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (de) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7030129B2 (en) * 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
AU2003279829A1 (en) * 2002-10-04 2004-05-04 Incyte Corp Protein modification and maintenance molecules
EP1466613A1 (de) * 2003-04-08 2004-10-13 Biotempt B.V. HCG-Fragmente enthaltene Zusammensetzungen zur mukosalen und oralen Anwendung
EP1466612A1 (de) * 2003-04-08 2004-10-13 Biotempt B.V. Behandlung von Entzündung und Sepsis mit hCG-Peptidderivate
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
EP1466611A1 (de) * 2003-04-08 2004-10-13 Biotempt B.V. Verwendung von HCG Peptidderivate zur Behandlung von iatrogene Krankheiten
EP1615655B1 (de) * 2003-04-08 2012-02-22 Biotempt B.V. Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006005190A1 (en) * 2004-07-14 2006-01-19 Inimex Pharmaceuticals Inc. Method of screening for protection from microbial infection
JP4910700B2 (ja) * 2004-08-30 2012-04-04 東レ株式会社 分画装置
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
EP1864692A1 (de) * 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
WO2008054532A2 (en) * 2006-05-08 2008-05-08 University Of Virginia Patent Foundation Compositions and methods for treating anthrax lethality
AU2008215193B2 (en) * 2007-02-12 2014-01-16 Biotempt B.V. Treatment of trauma hemorrhage with short oligopeptides
WO2009014440A1 (en) * 2007-07-23 2009-01-29 Biotempt B.V. Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides
US20090312249A1 (en) * 2007-12-06 2009-12-17 Korea Advanced Institute Of Science And Technology TLR4 decoy receptor protein
EP2109054A1 (de) 2008-04-09 2009-10-14 Biotempt B.V. Verfahren zur Identifizierung biologisch aktiver Peptide und Vorhersage ihrer Funktion
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
US8802680B2 (en) 2011-06-29 2014-08-12 The Penn State Research Foundation Compositions, methods and kits for treating leukemia
WO2014012165A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
US20190248885A1 (en) * 2016-10-26 2019-08-15 The Board Of Trustees Of The Leland Stanford Junior University Neuronal and Oligodendrocyte Survival Modulation
CN106801101B (zh) * 2017-02-23 2020-12-04 吉林大学 Med6基因作为急性心肌梗死风险预测标记物中的用途
CN111925411B (zh) * 2017-06-29 2022-04-08 安徽省农业科学院农产品加工研究所 一种含有Cys-Ser的高锌螯合活性锌螯合肽及其应用
CN110740558B (zh) * 2019-10-18 2021-05-07 南昌大学 一种测量等离子体电子非广延参数的方法
CN114901259B (zh) * 2019-12-30 2024-03-12 伊利亚斯生物制品公司 包含携带NF-kB抑制剂的外泌体的组合物及其使用方法
CA3166245A1 (en) * 2020-01-31 2021-08-05 Alireza Ebrahim Stable reference materials for automated hematology testing platforms
AU2021354766A1 (en) 2020-09-30 2023-05-11 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
CA3234504A1 (en) * 2021-10-05 2023-04-13 Biotempt B.V. Angiogenic control, preferably combined with glycaemic control.
CN113992687B (zh) * 2021-12-28 2022-04-08 浙江宇视科技有限公司 智能业务集群调度方法、装置、电子设备及存储介质

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2360794C2 (de) * 1973-12-06 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von Peptiden
US4108846A (en) * 1977-02-01 1978-08-22 Hoffmann-La Roche Inc. Solid phase synthesis with base N alpha-protecting group cleavage
JPS5822474B2 (ja) * 1980-06-10 1983-05-09 天野製薬株式会社 コレシストキニン・パンクレオザイミンｃ端ペプチドアミドスルフエ−トエステルの製造法
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US4571336A (en) * 1983-08-25 1986-02-18 Endorphin, Inc. Immune stimulation
US4977244A (en) * 1985-06-27 1990-12-11 The United States Of America As Represented By The Department Of Health And Human Services Uromodulin and a process of purifying it
US4855285A (en) * 1985-12-04 1989-08-08 The Ohio State University Research Foundation Antigenic modification of polypeptides
DK237187A (da) 1986-05-12 1987-11-13 Wellcome Found Farmaceutisk anvendelse af t-pa
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
US5002961A (en) * 1987-10-19 1991-03-26 Merrell Dow Pharmaceuticals Method for reducing injury with imidazol-2-thionecarboxamides
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
EP0341935B1 (de) * 1988-05-10 1996-04-10 Alpha-1 Biomedicals, Inc. Festphase-Verfahren zur Gewinnung von Thymosin-alpha-1
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US6309822B1 (en) * 1989-06-07 2001-10-30 Affymetrix, Inc. Method for comparing copy number of nucleic acid sequences
US5102393A (en) * 1989-07-17 1992-04-07 Survival Technology, Inc. Autoinjector converted from intramuscular to subcutaneous mode of injection
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
US6051596A (en) * 1990-08-10 2000-04-18 Anormed, Inc. Immunosuppressive compositions
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US5200507A (en) * 1991-04-12 1993-04-06 Mallinckrodt Specialty Chemicals Company Method of separating a peptide from a resin
US5223397A (en) * 1991-06-05 1993-06-29 Sangstat Medical Corporation Soluble hla cross-match
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
EP0633929B1 (de) * 1992-04-01 2004-03-03 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
ATE152734T1 (de) * 1992-05-30 1997-05-15 Sikiric Predrag Bpc-peptide, deren herstellung und verwendung
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
FR2706772A1 (en) 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
US5380668A (en) * 1993-07-06 1995-01-10 University Of Utah Research Foundation Compounds having the antigenicity of hCG
US5837478A (en) * 1993-12-23 1998-11-17 Icos Corporation Method of identifying modulators of binding between and VCAM-1
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5677275A (en) * 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
US5700781A (en) * 1994-10-04 1997-12-23 Harris; Pamela Jo Method for treating Kaposi's sarcoma and HIV infections
US5851997A (en) * 1994-10-04 1998-12-22 Harris; Pamela Jo Use of human chorionic gonadotropin as an immune-potentiating antiviral agent
WO1996032412A1 (fr) * 1995-04-13 1996-10-17 Chugai Seiyaku Kabushiki Kaisha PEPTIDE SUPPRIMANT LA PHOSPHORYLATION IxB$g(a)
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5942494A (en) * 1995-10-06 1999-08-24 The Trustees Of Columbia University In The City Of New York Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70)
US6159940A (en) * 1996-02-28 2000-12-12 Immunotech Developments Inc. Method for modulating hemopoiesis
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6361992B1 (en) * 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
US6207145B1 (en) * 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
US6319504B1 (en) * 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
AU3587797A (en) * 1996-06-24 1998-01-14 University Of Maryland Biotechnology Institute Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin
CA2180786C (en) * 1996-07-02 2008-05-27 David Lightfoot Plants containing the gdha gene and methods of use thereof
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
GB9617021D0 (en) * 1996-08-13 1996-09-25 Salpep Biotechnology Inc Novel peptides for treatment of inflammation and shock
GB9624927D0 (en) * 1996-11-29 1997-01-15 Oxford Glycosciences Uk Ltd Gels and their use
IL131410A0 (en) * 1997-02-15 2001-01-28 Proscript Inc Pharmaceutical compositions for treating infarcts through inhibition of nf-kappab
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
WO1998045704A2 (en) * 1997-04-07 1998-10-15 Bioimage A/S A method for extracting quantitative information relating to an influence on a cellular response
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6583109B1 (en) * 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
WO1999031227A2 (en) * 1997-12-12 1999-06-24 The University Of Western Ontario NOVEL PEPTIDE, apoEp1.B, COMPOSITIONS AND USES THEREOF
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6069129A (en) * 1998-03-13 2000-05-30 Mrs, Llc Elastin derived composition and method of using same
AU3147699A (en) 1998-03-27 1999-10-18 Andre Rosenthal Nucleic acid molecules which code proteins influencing bone development
US6022696A (en) * 1998-04-02 2000-02-08 Washington State University Research Foundation Methods of identifying agonists or antagonists of angiotensin IV
DE29808821U1 (de) 1998-05-17 1999-09-23 Gip Medizin Technik Gmbh Verband mit einem flachen Verbandsteil für die Aufnahme eines Kanülen-, Sonden- oder Katheterhalters
EP1138692A1 (de) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US20090042807A1 (en) * 1998-05-20 2009-02-12 Nisar Ahmed Khan Oligopeptide treatment of ischemia reperfusion injury
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
DE69911401T2 (de) * 1998-05-20 2004-06-24 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
AU4208799A (en) * 1998-05-29 1999-12-13 Human Genome Sciences, Inc. Interleukins-21 and 22
RU2139085C1 (ru) * 1998-06-23 1999-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Средство, стимулирующее репаративные процессы, и способ его применения
CA2342960C (en) * 1998-09-17 2010-03-09 Hopital Sainte-Justine G protein-coupled receptor antagonists
CN1341026A (zh) * 1998-12-03 2002-03-20 海斯塔泰克有限责任公司 治疗哮喘和炎症的小肽和方法
US6507788B1 (en) * 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6379970B1 (en) * 1999-04-30 2002-04-30 The Arizona Board Of Regents On Behalf Of The University Of Arizona Analysis of differential protein expression
RU2157233C1 (ru) * 1999-05-11 2000-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения
US7994278B1 (en) * 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
AU8014200A (en) * 1999-10-15 2001-04-30 Histatek, Llc N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent
RU2155063C1 (ru) 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
DE19953339A1 (de) 1999-11-05 2001-05-17 Goldham Pharma Gmbh Secretinfragmente
CA2389429C (en) * 1999-11-18 2012-05-29 Victor E. Shashoua Compositions and methods for counteracting effects of reactive oxygen species and free radicals
WO2001068113A1 (en) 2000-03-10 2001-09-20 Monsanto Technology Llc Anti-hypertensive peptides
US7576174B2 (en) * 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
EP1300418A1 (de) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US6783757B2 (en) * 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6539102B1 (en) * 2000-09-01 2003-03-25 Large Scale Proteomics Reference database
EP1217540A1 (de) * 2000-11-29 2002-06-26 Lafayette Software Inc. Methode zum Organisieren von Daten und zum Verarbeiten von Anfragen in einem Datenbanksystem, Datenbanksystem und Softwareprodukt zur Implementierung solcher Methode
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6894028B2 (en) * 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
WO2002085117A1 (en) 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
US20040072246A1 (en) * 2001-09-11 2004-04-15 Roland Martin System and method for identifying t cell and other epitopes and the like
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080242618A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Stratification
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20080194489A1 (en) * 2001-12-21 2008-08-14 Khan Nisar A Treatment of iatrogenic disease
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7135286B2 (en) * 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
WO2004016653A2 (en) * 2002-08-15 2004-02-26 Leukotech A/S Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) or human neutrophil elastase
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
IL157772A (en) * 2003-09-04 2016-06-30 Bmr Solutions Ltd Compounds containing oligopeptide derived from turtle larvae and their use to encourage mammalian hemophysis
US7638485B2 (en) * 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (de) * 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden

Also Published As

Publication number Publication date
EP2036924A2 (de) 2009-03-18
EP2036924B1 (de) 2011-11-30
IL161201A (en) 2010-06-16
US20050214943A1 (en) 2005-09-29
US20080176243A1 (en) 2008-07-24
EP2036924A3 (de) 2010-02-24
IL161201A0 (en) 2004-08-31
KR20040074975A (ko) 2004-08-26
CN1599753A (zh) 2005-03-23
EP2060585A2 (de) 2009-05-20
JP2005519867A (ja) 2005-07-07
EP2060585A3 (de) 2010-01-06
AU2008261169A1 (en) 2009-01-22
WO2003029292A2 (en) 2003-04-10
US7524820B1 (en) 2009-04-28
US20110105415A1 (en) 2011-05-05
CN101721676A (zh) 2010-06-09
NZ532173A (en) 2006-07-28
EP1432733B1 (de) 2011-07-27
ATE535542T1 (de) 2011-12-15
US20030113733A1 (en) 2003-06-19
HK1063327A1 (en) 2004-12-24
CA2462796A1 (en) 2003-04-10
WO2003029292A3 (en) 2003-12-11
EP1432733A2 (de) 2004-06-30
AU2002328028B2 (en) 2008-09-25
EP1300418A1 (de) 2003-04-09

Similar Documents

Publication Publication Date Title
ATE517915T1 (de) Methode zur identifikation gen-regulierender peptide
DK1218509T3 (da) Fibroblast vækstfaktorlignende polypeptider
DK1521774T3 (da) Trunkerede Tau-proteiner
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
WO2003104270A3 (en) GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES
DK1313762T3 (da) Suppressor-gen
DE69940888D1 (de) Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
DE3587875T3 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
PT1109021E (pt) Snail, novo marcador da progressao tumoral e proteina alvo de novos compostos antitumorais
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
DE602004007924D1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
ATE322906T1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
EA200500974A1 (ru) Антитело или антигенсвязывающий домен, специфически связывающиеся с полипептидом потенциалзависимого воротного ионного канала
DE602004032042D1 (de) Bibliotheken rekombinanter chimärischer proteine
WO2004047758A3 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE374593T1 (de) Methode zur haarbehandlung gekennzeichnet durch applikation bestimmter 2-hydroxyalkansäuren
HUP0200285A2 (hu) Glükóz-dehidrogenáz fúziós fehérjék és alkalmazásuk expressziós rendszerekben
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
HUP0203080A2 (hu) A PRV-1 gén és felhasználása
WO2002088345A3 (en) Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties